

Non-operative treatment of pediatric lateral humeral condyle fractures: a cohort study of 50 patients

Clinical Investigation Plan

File name: Study Protocol - Non-OP treatment of LHCF - H-21017621.pdf

Version and date: Version 3.0, 30 July 2021

Principal Coordinating Investigator

Morten Jon Andersen
MD

Department of Orthopedic Surgery
Copenhagen University Hospital –
Herlev and Gentofte,
Copenhagen, Denmark

Phone +45 38 68 14 79
Mobile +45 26 14 86 24
E-mail morten.jon.andersen@regionh.dk

Sponsor

Department of Orthopedic Surgery and
Department of Radiology and Scanning
Copenhagen University Hospital
Herlev and Gentofte
Copenhagen, Denmark

The Danish Data Protection Agency ID:
P-2020-1197

The Danish National Committee On Health
Research Ethics ID: H-21017621

Confidentiality statement

The information provided in this document is strictly confidential and is available for review to investigators, potential investigators and appropriate Ethics Committees (EC). No disclosure should take place without written authorization from the sponsor, except to the extent necessary to obtain informed consent from potential patients.

29 **Content**

30 Clinical Investigation Plan 1

31 Principal Coordinating Investigator 1

32 Sponsor 1

33 Confidentiality statement..... 1

34 Abbreviations/glossary 4

35 Definitions 4

36 1 Synopsis..... 5

37 2 Rationale and purpose of the study 8

38 3 General information/responsibilities..... 8

39 3.1 Responsibilities..... 8

40 4 Background and literature review 9

41 4.1 Definition and epidemiology 9

42 4.2 Diagnosis 9

43 4.3 Outcome 9

44 4.4 Current status of research in this area 9

45 5 Primary and secondary objectives 11

46 5.1 Primary objective 11

47 5.2 Secondary objective(s)..... 11

48 5.3 Hypothesis 11

49 6 Study design..... 11

50 6.1 Study population and patient enrollment..... 11

51 6.2 Study procedures 13

52 6.3 Study treatments 15

53 7 Definitions of outcome measures and study variables 18

54 7.1 Primary outcome 18

55 7.2 Secondary outcomes..... 19

56 8 Statistical planning 21

57 8.1 Hypotheses..... 21

58 8.2 Sample size considerations..... 21

59 8.3 Statistical analysis 21

60 9 Bias 21

61 10 Benefits 22

62 11 Risk analysis 22

63 11.1 Treatment-related risks 22

64 11.2 Study disadvantages 22

65 11.3 Study-related risks 22

66 11.4 Actions to minimize increased risks 23

67 12 Informed consent process 23

68 12.1 Special considerations to consent pediatric patients 23

69 13 Adverse event reporting 24

70 14 Data management 24

71 14.1 Data collection, source data, storage and archiving 24

72 14.2 Imaging data 25

73 14.3 Confidentiality 25

74 15 Regulatory affairs 25

75 16 Disclosures and economy 25

76 17 Patient insurance 25

77 18 Study report and publication policy 25

78 18.1 Final Study Report 25

79 18.2 Publication 26

80 19 Termination criteria 26

81 19.1 Stopping rules 26

82 20 Deviations from the Clinical Investigation Plan 26

83 21 Amendments to the Clinical Investigation Plan 26

84 22 Time schedule 27

85 23 Authors 27

86 24 Reference list 28

87 Appendix 1 - Diagnosis and Treatment Protocol 31

88

89

90

91 **Abbreviations/glossary**

AE/SAE	Adverse Event(s)/Serious Adverse Event(s)
ADE/SADE	Adverse Device Event(s)/Serious Adverse Device Event(s)
AO	Arbeitsgemeinschaft für Osteosynthesefragen = Association for the Study of Internal Fixation (ASIF)
CIP	Clinical Investigation Plan
CRF	Case Report Form
CRO	Contract Research Organization = Clinical Research Organization
EC	Ethics Committee
eCRF	Electronic Case Report Form
EDC	Electronic Data Capture
FSR	Final Study Report
FU(s)	Follow-up(s), eg follow-up visit(s), follow-up procedure(s)
GA	General Anesthesia
GCP	Good Clinical Practice
ICF	Informed Consent Form
ICH	International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use
ISF	Investigator Site File
ISO	International Organization for Standardization
LHCF	Lateral Humeral Condyle Fracture
MeSH	Medical Subject Heading
MRI	Magnetic Resonance Imaging
PCI	Principal Coordinating Investigator (= Principal Clinical Investigator)
PI	Principal Investigator
SD	Standard Deviation
U(S)ADE	Unanticipated (Serious) Adverse Device Effect

92
 93 **Definitions**

Baseline	Status post injury but pretreatment
Enrolled	Patients with written informed consent who commenced treatment within the study
Follow-up visit	FU; visit at predefined times after the treatment day
Follow-up population	Patients intended to be followed-up (i.e. enrolled population)
Injury day	"Day 0"; day of injury
Written informed consent	Legally binding signature on the informed consent form (ICF) (i.e. the patient's parents or legal guardians)

94

1 Synopsis

Official title	Non-operative treatment of pediatric lateral humeral condyle fractures: a cohort study of 50 patients
Short title	Non-operative treatment of pediatric lateral humeral condyle fractures
Sponsor	Department of Orthopedic Surgery Copenhagen University Hospital – Herlev and Gentofte
Registration	The study will be registered with ClinicalTrials.gov
Background and purpose	The diagnosis of LHCF is complicated by radiographic inability to show the full extent of the injury into the chondral (unossified) epiphysis. MRI gives a perfect view of these fractures. The safety and feasibility of non-operative treatment based on MRI findings in children with elbow fractures has not been investigated in a Danish setting. If safe and feasible, the use of MRI could dramatically lower the need for surgery in children with LHCF.
Condition	Pediatric lateral humeral condyle fracture
Intervention/procedure investigated	Non-operative treatment of LHCF based on MRI findings
Comparison	None
Study type	Interventional
Study design	Prospective, Cohort, Single center
Short description	Cohort study of 50 patients aged 2-15 with acute LHCF. Intervention with non-operative treatment based on MRI performed without sedation or anesthesia. Objectives are to describe functional outcome, radiological healing, secondary fracture displacement and any complications after two years. Patients are seen for follow-up 1, 2 and 4 weeks and 3, 6, 12 and 24 months after injury. The investigators hypothesize that undisplaced and minimally displaced LHCF can be treated non-operatively based on MRI findings with good functional outcomes after two years.
Primary objective	Describe the functional outcome two years after non-operative treatment of undisplaced and minimally displaced LHCF in children.
Secondary objectives	<ul style="list-style-type: none"> Describe the feasibility of performing a subacute MRI of the elbow in children with LHCF within 2-7 days after the injury without sedation or anesthesia Report MRI findings and classify fractures according to Song classification based on MRI Report the number and proportion of fractures that displace secondarily and their treatment Report final treatment; non-operative or operative Describe radiographic results and compare with MRI Report any early or late complications

Hypothesis	Children with minimally displaced LHCF (Song stage 1, 2 and 3) can be treated non-operatively based on MRI findings with good functional outcome after two years.
Primary outcome measure	Mayo Elbow Performance Score (MEPS) two years after injury
Secondary outcome measures	<ul style="list-style-type: none"> • Pain • Radiographic results • MRI results • Alteration in treatment regime based on MRI • Number and proportion of fractures with secondary displacement • Any early or late complications
Statistical considerations and estimated enrollment	<p>Sample size is estimated from previous studies which included less than 30 participants. The investigators of this study suspect that by enrolling 50 participants the age distribution and variation in fracture pattern will be representative of the background population.</p> <p>Baseline characteristics and outcomes recorded at scheduled FU assessments will be presented using simple summary statistics.</p>
Start of enrollment	October 2021 (estimated)
Last patient/last visit	October 2025 (estimated)
Eligibility inclusion criteria	<p>Inclusion criteria:</p> <ul style="list-style-type: none"> • Children age 2-15 years • Diagnosis of acute LHCF (<5 days) with <5 mm of displacement on plain radiographs • Parental informed consent obtained
Eligibility exclusion criteria	<p>Exclusion criteria:</p> <ul style="list-style-type: none"> • Contraindication(s) to performing an MRI • Unable to participate in follow-up • Existing bone pathology • Previous ipsilateral elbow fracture
Principal Coordinating Investigator	<p>Morten Jon Andersen, MD Department of Orthopedic Surgery Copenhagen University Hospital – Herlev and Gentofte Copenhagen, Denmark</p> <p>Phone +45 38 68 14 79 Mobile +45 26 14 86 24 E-Mail morten.jon.andersen@regionh.dk</p>
Study site	<p>Department of Orthopedic Surgery Copenhagen University Hospital – Herlev and Gentofte Copenhagen, Denmark</p>
Health authority	<p>The Danish Data Protection Agency The Danish National Committee On Health Research Ethics</p>

<p>Pubmed Medical Subject Heading [MeSH] terms and keywords</p>	<p>Child [MeSH] Casts, Surgical [MeSH] Fracture Fixation [MeSH] Humeral Fractures [MeSH]</p>
<p>Imaging review</p>	<p>All images collected will be analyzed by independent radiologists during the study</p>

96

97

98 2 Rationale and purpose of the study

99 The treatment of LHCF is most often surgical with open reduction and fixation [1]. The diagnosis of
100 LHCF is complicated by radiographic inability to show the full extent of the injury into the unossified
101 chondral epiphysis and therefore physicians often opt for open surgical treatment. MRI; however, gives
102 a perfect view of these fractures [2–5]. This project investigates the safety and feasibility of non-
103 operative treatment of LHCF based on MRI performed without sedation or anesthesia and seeks to
104 dramatically lower the need for surgery. Objectives are to describe functional outcome, radiological
105 healing, secondary fracture displacement and any complications after two years. The investigators
106 hypothesize that undisplaced and minimally displaced LHCF can be treated non-operatively based on
107 MRI findings with good functional outcomes after two years. A cohort study design is used to follow 50
108 children with LHCF.

109 3 General information/responsibilities

110 The International Conference on Harmonization for Good Clinical Practice (ICH-GCP) and ISO 14155
111 guidelines define the responsibilities of the sponsor and investigators in the context of the study.
112 Specific topics, such as the permission from the responsible EC, are defined separately in the CIP. The
113 study site undertakes to guarantee correct and prompt implementation, documentation, and
114 transmission of the study data.

115
116 In the context of the study, the participating study site will return the completely documented cases.
117 Completely documented means that all FU visits have been carried out for the cases included in the
118 study and that these assessments are recorded on the electronic Case Report Forms (eCRFs) specially
119 designed for this study. Furthermore, the necessary radiological investigations must be performed at the
120 FU visits.

121 3.1 Responsibilities

Principal Coordinating Investigator
Morten Jon Andersen
MD

Department of Orthopedic Surgery Copenhagen
University Hospital - Herlev
and Gentofte, Copenhagen, Denmark

Phone +45 38 68 14 79
Mobile +45 26 14 86 24
E-Mail morten.jon.andersen@regionh.dk

Sponsor
Copenhagen University Hospital
Herlev and Gentofte

Department of Orthopedic Surgery and
Department of Radiology and Scanning
Copenhagen University Hospital
Herlev and Gentofte
Copenhagen, Denmark

122
123
124
125
126

127 4 Background and literature review

128 4.1 Definition and epidemiology

129

130 Fractures of the distal humerus account for 5-10% of all pediatric fractures but constitute up to 30% in
131 children aged 4-9 years of age [6–10]. Fractures of the lateral humeral condyle account for 10-20% of
132 all elbow fractures in children making it the second most frequent after supracondylar fractures
133 [3,11,12].

134

135 LHCF are usually the result of a fall on an outstretched arm with either the extensor-supinator mass
136 pulling or the radial head pushing off the lateral condyle [13]. The diagnosis is suspected by the history
137 of a fall, usually a swollen and painful elbow with tenderness over the lateral aspect. In more severe
138 cases a hematoma can present early.

139

140 A LHCF is a Salter-Harris type II or IV physeal fracture which can appear as everything from a hairline
141 fracture to grossly displaced intraarticular injuries.

142 4.2 Diagnosis

143

144 Fractures are usually diagnosed on plain radiographs with antero-posterior (AP), medial-lateral (ML)
145 and internal oblique (IO) radiographs. Especially the IO is important in appreciating the amount of
146 displacement [14]. The distal humerus, especially in younger children, is largely composed of cartilage
147 and is termed the chondroepiphysis [7]. Four secondary ossification centers arise with growth at
148 different ages making interpretation of elbow radiographs in children a challenge [15]. A study showed
149 that emergency department (ED) physicians only made the right radiographic diagnosis in 53% (16/30)
150 of cases concerning pediatric elbow injuries [16].

151 4.3 Outcome

152

153 Neglecting to treat displaced LHCF can lead to painful nonunion, malunion and growth disturbances e.g.
154 fishtail deformity. Complications such as tardy ulnar nerve palsy and varus or valgus deformity can
155 develop years after an untreated injury [13].

156 4.4 Current status of research in this area

157

158 Undisplaced and minimally displaced LHCF found on radiographs compose a specific challenge in
159 choosing between non-operative or operative treatment [13]. The risk of secondary displacement of an
160 initially undisplaced fracture varies from 4% to more than 40% depending on the initial stability and
161 displacement [12].

162

163 Historically these fractures were classified according to Milch [17] however this system neither
164 describes fracture stability nor focusses on fractures in children and has no prognostic value [1].


165

166 Song's classification (figure 1) [18] discerns incomplete from complete and undisplaced from displaced
167 fractures clearly describing fracture stability.

168

169 Song stage 1 fractures only involve the bony metaphysis. Stage 2 fractures pass into the
170 chondroepiphysis, but not through, leaving the articular cartilage intact and functioning as a hinge [4].

171 Stage 1 and 2 fractures are considered stable and can be treated non-operatively. Stage 3 fractures are
 172 complete and traverse the entire course of the metaphysis, chondroepiphysis and the articular cartilage
 173 leaving the fragment without any attachment. These fractures can be undisplaced but are always
 174 considered unstable. Treatment controversy arises from the inability to distinguishing stage 1 and 2
 175 from stage 3 on plain radiographs.
 176




177
 178
 179

Figure 1 - Song classification.

180 Because of the risk of secondary displacement, operative treatment is often conducted with many
 181 surgeons choosing open reduction and fixation in all cases [19,20]. Operative fixation imposes the risk
 182 of minor complications such as superficial infection, ulcers and granulomas but also major complications
 183 such as deep infection, osteomyelitis, malunion, non-union, growth disturbance and osteonecrosis [21].
 184

185 MRI with specific cartilage sequences (figure 2) can clearly show the chondroepiphysis and studies
 186 have shown that MRI is capable of precisely showing the fracture pattern [2,3,5,22]. Using simple
 187 techniques and advances in technology to prepare the child, MRI has been shown to be feasible in
 188 younger children without sedation or anesthesia in whom this was previously thought necessary [23–
 189 30].
 190



191
 192
 193
 194

Figure 2 - MRI showing LHC. Left: Stage 1, confined to metaphysis. Center: Stage 2, fracture line stops in the chondroepiphysis. Right: Stage 3, traverses the joint cartilage.

195

196 5 Primary and secondary objectives

197 5.1 Primary objective

198

199 To describe the functional outcome two years after non-operative treatment of undisplaced and
200 minimally displaced LHCF in children.

201 5.2 Secondary objective(s)

202

- 203 • Describe the feasibility of performing a subacute MRI of the elbow in children with LHCF within 2-7
- 204 days after the injury without sedation or anesthesia
- 205 • Report MRI findings and classify fractures according to Song classification based on MRI
- 206 • Report the number and proportion of fractures that displace secondarily and their treatment
- 207 • Report final treatment; non-operative or operative
- 208 • Describe radiographic results and compare with MRI
- 209 • Report any early or late complications

210 5.3 Hypothesis

211

212 Children with minimally displaced LHCF (Song stage 1, 2 and 3) can be treated non-operatively based
213 on MRI findings with good functional outcome after two years.

214 6 Study design

215 This project uses a cohort study design conformed to the STROBE Statement [31]. The investigators
216 aim to prospectively and consecutively recruit all children with undisplaced or minimally displaced LHCF
217 (cohort) which based on MRI are treated non-operatively (exposure). We report functional and
218 radiological outcome two years after the injury (outcome). This study design is relevant in reporting the
219 primary and secondary outcomes based on the exposure in our cohort.

220 6.1 Study population and patient enrollment

221

222 This study investigates the treatment of pediatric LHCF; therefore, this study cannot be conducted in
223 consenting adults. LHCF occur predominantly in 4-9 year olds and thus it is not possible to select only
224 older children for inclusion.

225

226 This study is believed to have great positive implications for the participants and successive patients
227 with the same condition.

228 6.1.1 Setting

229

230 The study will be performed in the Capitol Region of Denmark. Patients in the catchment area of
231 Copenhagen University Hospital – Herlev and Gentofte are eligible for recruitment (population 700.000
232 of which 80.000 are children).

233 6.1.2 Inclusion criteria

- 234 • Children aged 2-13 years
- 235 • Diagnosis of acute LHCF
 - 236 – Fracture <5 days old
 - 237 – Fracture with <5 mm of displacement on plain radiographs (AP, ML and IO views)
- 238
- 239 • Parental informed consent obtained:
 - 240 – Ability of all legal guardians to understand the content of the patient information and ICF
 - 241 – Willingness and ability to let the child participate in the clinical investigation according to the
 - 242 Clinical Investigation Plan (CIP)
 - 243 – Signed and dated EC-approved written parental informed consent sheet

244 6.1.3 Exclusion criteria

- 245 • Contraindication(s) to performing an MRI [32] without the use of sedation or anesthesia:
 - 246 – Ferromagnetic implants or foreign bodies
 - 247 – Pacemaker
 - 248 – Ear implant
 - 249 – Severe claustrophobia
- 250 • Unable to participate in follow-up
- 251 • Existing bone pathology
 - 252 – Tumor
 - 253 – Osteogenesis imperfecta
 - 254 – Degenerative disease
- 255 • Previous ipsilateral elbow fracture

256 6.1.4 Enrollment of participants

257 A member of the research team will identify all eligible patients (i.e., who meet all of the inclusion and
258 none of the exclusion criteria).

259

260 The identification of eligible patients is done during the daily routine review of radiographs taken in the
261 ED of Copenhagen University Hospital - Herlev and Gentofte.

262

263 Electronic letters for FU cannot be sent to minors; therefore all parents are routinely approached by
264 phone. During this standard approach we ask permission from the EC to inquire the parents about their
265 interest and their child's eligibility in participating in this study. This inquiry will include a short
266 prescreening with questions to confirm eligibility as well as a short description of the study and
267 responsibilities for participating. None of the data of the pre-screening process will be documented
268 study specifically.

269

270 If interested in participating, the parents and the patient are invited to the outpatient clinic. Parents are
271 informed of the possibility of bringing an assessor. At the visit, a member of the research team will go
272 through the informed consent process, and explain the purpose of the study, the procedures, the
273 risk/benefits, alternatives to participation, and data protection.

274

275 For each patient participating the parents will sign and date an ICF. A copy of the signed ICF will be
276 placed into the ISF and one copy will be handed over to the parents. A more detailed description of the
277 informed consent process is provided in section 12.

278 All patients with written informed consent will be allocated to a unique patient trial number. The date of
 279 informed consent and the recruitment information is entered in the study database.

280

281 The recruitment period will be up to 24 months, during which 50 patients are planned to be enrolled.

282 **6.2 Study procedures**

283

284 The schedule of all FU visits including imaging procedures as well as the data to be collected at each
 285 visit is shown in Table 1. All FU visits with the defined time windows are calculated from the day of injury
 286 (i.e. day 0).

287

288 All participants live in the catchment area of Herlev and Gentofte Hospital within short transportation
 289 time. Information about the time and place for the follow-up examination is sent physically by mail to the
 290 current address registered in the Civil Registration System and via the electronic health record (EHR)
 291 system. Parents are usually very keen to take their children for follow-up appointments making the risk
 292 of missing an appointment low. Any participants who miss an appointment will be contacted by phone to
 293 reschedule.

294

295 Table 1: Study schedule

296

Assessment parameters	Out-patient clinic visits and imaging procedures *										
	Visit 1**	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10	
	Injury (day 0)	Screening	Information visit	Enrollment and consent	5 (± 3) days	12 (± 3) days	4 weeks	3 months	6 months	12 months	24 months
Eligibility	X										
Patient information		X									
Consent			X								
Demographics			X								
MRI				X							
<i>If applicable - Control-MRI</i>					(X)						
Cast removal***						X					
Radiographs and clinical exam					X	X	X	X	X	X	

297

298 * All FU visits with the defined time windows are calculated from the day of injury (i.e. day 0).

299 ** Telephone interview.

300 *** Casting may be prolonged two weeks in case of lack of callus formation at four weeks.

301

302 6.2.1 Visit 1: Screening (by phone)

- 303 • As described in section 6.1.4, the parents of potential study patients are informed about the study
304 over telephone by the PI.

305 6.2.2 Visit 2: Information visit

- 306 • All inclusion and exclusion criteria are checked to decide if the patient can participate in the study.
307 • Specific procedures for enrollment of pediatric patients are undertaken. A more detailed description
308 of the enrolment of participants and informed consent process is provided in section 6.1.4 and 10.
309 • Before any study-specific examinations are performed, the patient's parents give written informed
310 consent to participate in the study according to the CIP.

311 6.2.3 Visit 3: Enrolment, consent and preparation for MRI

- 312 • Obtain baseline demographics
313 • Book MRI
314 • Prepare child for MRI using the Child Centered Care model described in section 6.3
315 • Data verification and entry into the eCRF

316 6.2.4 Visit 4: MRI (5 (± 3) days)

- 317 • The MRI is performed according to the Child Centered Care model described in section 6.3
318 • Results of the MRI are given to the parents by phone
319 • Any necessary adjustments to the treatment plan is made
320 • Entry into the eCRF

321 6.2.5 ONLY if applicable: Control-MRI (12 (± 3) days)

- 322 • If an unstable Song stage 3 fracture is diagnosed based on the initial MRI an additional control MRI
323 is performed during this visit
324 • Results of the MRI are given to the parents by phone
325 • Any necessary adjustments to the treatment plan is made
326 • Entry into the eCRF

327 6.2.6 Visit 5: Radiographs and clinical examination (12 (± 3) days)

- 328 • Plain radiographs of injured elbow without cast (AP, ML and IO)
329 • Clinical examination
330 – Cast condition
331 – Assessment of pain and use of pain medication
332 – Neurovascular status of the hand
333 • Entry into the eCRF

**334 6.2.7 Visit 6, 7, 8, 9 and 10: Radiographs and clinical examination (4 weeks and 3, 6, 12 and 24
335 months).**

- 336 • Plain radiographs of injured elbow without cast (AP, ML and IO)
337 • Clinical examination
338 – Assessment of pain and use of pain medication
339 – Neurovascular status of the hand
340 – Bilateral elbow assessment according to Mayo Elbow Performance Score (MEPS)
341 – Bilateral carrying angle of the elbow measured in degrees by goniometer
342 • Entry into the eCRF

343 **6.2.8 Unscheduled visits**

344 Unscheduled visits can take place at any time during the study if a need occurs or if the investigator
345 considers this to be appropriate for patient care. Information collected between study visits are to be
346 documented at the next regular study visit with the following exceptions:

- 347 • If a patient drops out of the study, a dropout form is completed at the time of dropout

348 **6.2.9 Premature study termination**

349 Patient participation in the study may end prematurely for one of the following reasons:

- 350 • Patient withdrew informed consent
- 351 • Protocol violation
- 352 • Investigator's discretion (e.g. patient noncompliance with CIP)
- 353 • Unknown/lost to FU

354

355 For each case of premature termination detailed information will be obtained explaining the
356 circumstances leading to the termination. This will be recorded on a dropout form in the eCRF.

357

358 If patients are withdrawn from the study, any collected data will be censored. Censoring allows this
359 collection of data to be accounted for in the analysis.

360 **6.3 Study treatments**

361

362 This study is not investigating any medical device. All devices in this study will be used per standard of
363 care at the participating institutions.

364 **6.3.1 Emergency treatment**

365 All patients who sustain a LHCF are initially treated in the ED with an above elbow splint. Parents and,
366 when applicable, the patient are informed of the injury, cast management and use of pain medicine.

367 **6.3.2 MRI in children without sedation or anesthesia**

368 Child Centered Care (CCC) (figure 3 and 4) consists of:

- 369 • Oral and written information about MRI together with a demonstration of the process using a toy
370 scanner is given by a member of the research team to parents and patient.
- 371 • Movies from the hospital's radiology department that prepare the child for the experience.
- 372 • An interactive app (Rumble in MRI, free in App Store and Google Play Store) that prepares and
373 motivates the child. The troll character Rumble and 3D animations of rooms increase recognisability.
- 374 • A pediatric team of radiographers focus on the child feeling safe and secure.
- 375 • A child-friendly environment in the MRI room with lights and movies coordinated in themes known
376 from the app projected on the wall ("Philips Ambient Experience", Philips Electronics, Koninklijke,
377 Netherlands).

378



379
380
381

Figure 3 - Left) Rumble in MRI app. Right) Toy scanner from Playmobil® used to show children the procedure.

382 To further better the child's experience, all MRIs are performed during daytime hours, preferably before
 383 noon. Parents are asked to give the child pain medicine according to age and weight before leaving
 384 home. Scans are performed with an above elbow splint on.

385 6.3.3 MRI protocol

386 MRI examination (figure 4) of the elbow is performed using Philips dStream S flex coils on 3 Tesla MRI
 387 scanners (Philips Ingenia Elition X 3T and Philips Ingenia 3T). Patients undergoing the examination will
 388 have a splint on with the elbow flexed to 90 degrees. The splinted elbow is lowered beside the patient,
 389 removing the respiratory artifact. The dStream S flex coils include two flexible coils which can obtain 10
 390 cm coverage with a maximum of four channels. These coils are placed around the patients elbow
 391 parallel to each other, and perpendicular to the static magnetization field.

392



393
394
395

Figure 4 – A pediatric team of radiographers focus on the child feeling safe and secure.

396 The MRI protocol consists of three sequences with breaks in between; 3D WATS - 2 minutes and 32
 397 seconds, T1 coronal – 2 minutes and 16 seconds and STIR coronal 3 minutes and 53 seconds. Total
 398 scan time is less than 9 minutes. The most important information comes from the 3D WATS sequence
 399 and in most cases the derived images will be sufficient to choose between non-operative or operative
 400 treatment.

401

402 In total, 45 minutes is set aside for receiving and briefing patient and parents, positioning the child and
 403 completing the scans. Parents are invited to sit next to the child during the scan. The radiographers
 404 involve the children by dialog and each child can choose the color of the room. The child holds the stop

405 button in his or her hand, so that they can press stop along the way. Communication with radiographers
406 is possible throughout the procedure. The procedure is stopped at any request from the child or parents
407 or if deemed necessary by the radiographers.

408

409 **3D Water Selective Excitation (WATS)**

410 3D WATS is a fast field echo T1 weighted pulse sequence [33]. 3D WATS utilizes the chemical shift
411 artifact to differentiate between the frequencies of fat and water. The sequence applies a technique
412 where the water protons are selectively excited to induce fat suppression in cartilage. WATS is a 3D
413 imagery so it can be reconstructed with various slices in the computer after the scan. The 3D WATS
414 sequence is usually used for evaluation of cartilage.

415

416 **T1**

417 T1 weighted images results from the differences in the T1 recovery times of the tissues. In T1
418 sequences, fat and degeneration has a high signal, where cortical bone, infection and cysts has a low
419 signal. T1 weighted images are used to portray the anatomy.

420

421 **Short Tau Inversion Recovery (STIR)**

422 STIR is a pulse sequence that suppresses the signal from fat [34]. STIR is an important sequence in
423 musculoskeletal imaging showing lesions inside of the bone. A normal bone contains fat bone marrow
424 and STIR suppresses fat which shows lesions with bone marrow edema.

425

426 Table 2: Specific scan parameters and scan times

Parameter	3D WATS	T1 COR	STIR COR
TR	20	Range (450-750) 750	3536
TE	4.9	9	60
FA	15	90	<i>Inversion Recovery: 220 msec. Refocusing angle: 90*</i>
Scan mode	3D	2D	2D
Technique	FFE	SE (TSE)	IR (TSE)
Slice thickness	3 mm	3 mm	3 mm
Interslice gap	-1.5 mm	0.3 mm	0.3 mm
FOV	150 x 150	140 x 140	130 x 130
Voxel	0.493 x 0.493	0.5 x 0.53	0.6 x 0.74
Time	2.32 min	2.16 min	3.53 min

427 **6.3.4 MRI results**

428 The results of the MRI are reconstructed and read by senior MRI radiologists together with the PI.
429 Patient and parents are informed of the MRI findings and the following treatment (operative or non-
430 operative) by the PI.

431 **6.3.5 Operative treatment**

432 If the MRI cannot be completed for any reason, the images are insufficient in establishing fracture
433 pattern or if the MRI shows an unstable fracture which is displaced more than 2 mm, we will suggest
434 operative treatment with Kirschner wire fixation. Further participation in this project will be terminated.

435 **6.3.6 Non-operative treatment**

436 Patients with undisplaced and minimally displaced LHCF as seen on MRI will follow a non-operative
 437 treatment protocol (appendix 1). The treatment consists of an above elbow splint until radiographic
 438 union. Radiographic union usually occurs after four weeks; however, treatment will be continued until
 439 callus formation is seen at the cortex of the metaphysis.

440
 441 Fractures that are not complete (e.g., do not traverse both metaphysis, physis, epiphysis and joint
 442 cartilage) are considered stable. Complete fractures displaced <2 mm are considered unstable but still
 443 eligible for non-operative treatment. All patients will be seen for FU as outlined in section 6.2.

444
 445 Any patient with a fracture seen to displace more than 2 mm during FU will be suggested operative
 446 treatment.

447 **7 Definitions of outcome measures and study variables**

448 **7.1 Primary outcome**

449 **7.1.1 Mayo Elbow Performance Score (MEPS)**

450 MEPS consists of four domains; pain, elbow range of motion (ROM), stability and function [35]. We use
 451 a modified MEPS which omits the functional domain because it is not relevant in smaller children. The
 452 total score ranges from 0-100 with higher scores indicating better function (figure 5). If the total score
 453 ranges between 75 and 100, the result is good (satisfactory); 50–74, fair (acceptable); <50, poor
 454 (unsatisfactory) [36]. MEPS has been found to be accurate and reliable compared to other elbow
 455 scoring systems [37].

Criteria	No. of points
PAIN (max., 60 points)	
None	60
Mild to occasional, no medication	40
Moderate to occasional, activity limited, medication	20
Severe to incapacitating	0
MOTION (max. 30 points)	
Arc of extension/flexion:	
>90	30
60–89	20
30–59	10
<30	0
STABILITY (max., 10 points)	
Effect on function of the elbow	
None or mild (does not limit activity)	10
Moderate (impairs certain functions)	5
Severe (markedly limits activity)	0

456 **Figure 5 - Modified Mayo Elbow Performance Score.**
 457

458

459 **7.2 Secondary outcomes**

460 **7.2.1 MRI results**

- 461 • Proportion of successful MRIs defined as a completed scan with an image quality that is useful for
- 462 analysis by the radiologist.
- 463 • MRI findings.
- 464 • Song classification based on MRI.
- 465 • Scan length (minutes).
- 466 • Any discomforts for the child during the scan.

467 **7.2.2 Radiographic results**

468 Injury radiographs and subsequent radiographs during FU will be read and described by a senior
 469 orthopedic surgeon.

470 **7.2.3 Secondary displacement**

471 Any secondary displacement and amount of radiographic displacement (mm) is recorded.

472 **7.2.4 Pain**

473 To quantify pain in the patient, an age appropriate rating scale is applied:

- 474 • Age <5 years: Face, Legs, Activity, Cry, Consolability Scale (FLACC)
- 475 • Age >4 years: Faces Pain Scale – Revised (FPS-R)
- 476 • Age >8 years: Visual analogue scale

477 **Face, Legs, Activity, Cry, Consolability Scale (FLACC)**

479 To quantify pain behaviors in children who may not be able to verbalize the presence or severity of pain
 480 FLACC [38] provides a simple framework. The child is observed for at least 2-5 minutes. Legs and body
 481 are observed uncovered. Activity is observed and body is assessed for tenseness and tone.

482

Behavior	0	1	2
Face	No particular expression or smile	Occasional grimace or frown, withdrawn, disinterested	Frequent to constant quivering chin, clenched jaw
Legs	Normal position or relaxed	Uneasy, restless, tense	Kicking or legs drawn up
Activity	Lying quietly, normal position, moves easily	Squirming, shifting, back and forth, tense	Arched, rigid or jerking
Cry	No cry (awake or asleep)	Moans or whimpers; occasional complaint	Crying steadily, screams, sobs, frequent complaints
Consolability	Content, relaxed	Reassured by touching, hugging or being talked to, distractible	Difficult to console or comfort

483

484 Assessment of Behavioural Score:

- 485 • 0 = Relaxed and comfortable
- 486 • 1-3 = Mild discomfort
- 487 • 4-6 = Moderate pain
- 488 • 7-10 = Severe discomfort/pain

489


490

491

492

493 Faces Pain Scale – Revised (FPS-R)

494 The Faces Pain Scale – Revised (FPS-R) [39] is used to quantify pain in children above four years of
 495 age. It is a self-report measure of pain intensity developed for children. It was adapted from the Faces
 496 Pain Scale [40] to make it possible to score the sensation of pain on a 0-to-10 metric. The scale shows
 497 a close linear relationship with visual analog pain scales (VAS) across the age range of 4-16 years.
 498




499
 500 **Figure 6 - Faces of the FPS-R. The child is instructed to point to the faces that shows how much pain the child is in at**
 501 **that moment. Faces are scored 0, 2, 4, 6, 8 or 10 from left to right.**

502
 503 FPS-R is easy to administer and requires no equipment except for the photocopied faces (figure 6). The
 504 child is asked to point to the face that shows how much pain the child is in at that moment. Faces are
 505 scored 0-10 so 0 equals no pain and 10 equals very much pain.
 506

507 Visual analogue scale

508 A visual analogue scale (VAS) (Figure 7) is used to quantify pain in children age 8 and above. VAS has
 509 been extensively investigated in quantifying pain in older children [41,42]. The child is asked to put a
 510 mark on the line corresponding to the child's pain at that moment. A mark to the far left equals no pain
 511 and a mark to the far right equals worst possible pain. The line is 10 cm long and the child's mark is
 512 measured from left to right in cm with one decimal e.g., 3.4 cm equaling a VAS of 3.4. If the child cannot
 513 cooperate to using VAS, FPS-R is used instead.
 514
 515



516
 517 **Figure 7 - Visual analogue scale (VAS) for quantifying pain in children age 8 and above.**

518
 519
 520
 521
 522

523 8 Statistical planning

524 8.1 Hypotheses

525

526 Minimally displaced LHCF (Song stage 1, 2 and 3) can be treated non-operatively based on MRI
527 findings with good functional outcomes after two years.

528 8.2 Sample size considerations

529

530 Samples size is estimated from previous studies which included less than 30 participants [22,23]. The
531 investigators of this study suspect that by enrolling 50 participants the age distribution and fracture
532 pattern variation will be representative of the background population. By enrolling 50 patients the
533 investigators suspect that any frequent and serious complications will be found.

534 8.3 Statistical analysis

535

536 Baseline characteristics and outcomes recorded at scheduled FU assessments will be presented using
537 simple summary statistics.

538

- 539 • Categorical variables will be summarized using the frequency and percentage for each category.
- 540 • Continuous variables will be summarized using the mean, standard deviation (SD), median, inter-
541 quartile range, and minimum and maximum values and, if appropriate, according to clinically relevant
542 categories.

543

544 In general, continuous variables with both baseline and FU measurements available will also be
545 summarized in terms of the individual patient-level changes between baseline and follow-up.

546

547 A p-value of <0.05 is regarded as being significant. Data will be analyzed using SPSS (SPSS, Chicago,
548 IL, USA).

549 8.3.1 Patient discontinuation

550

551 If a participant chooses to discontinue the follow-up examinations for any reason, the date and reason
552 for drop-out is recorded and the latest examination will be carried forward in the analysis. In case of
553 drop-out before the first follow-up visit the participant will be excluded from the analysis. Participants are
only removed from the study if they decline participation.

554 9 Bias

555

556 We strive to minimize bias in our study. Minimally displaced fractures of the elbow can go unnoticed and
557 be missed by our project. However, Danish parents are usually not withholding in taking an injured child
558 to the ED. A strict protocol for referrals for treatment are in place in Denmark. All eligible patients
559 referred to Herlev and Gentofte University Hospital will be asked to participate in the study. We
560 speculate that by enrolling 50 participants the cohort will be representative of the background
561 population. We speculate that these efforts will limit selection bias. Efforts described in the follow-up
562 section reduce the risk of loss to follow-up. Overall, we find a low risk of bias in our study for the chosen
study design and size.

563 10 Benefits

564 Classifying lateral condyle fractures and establishing whether they are stable or not is the key to
565 choosing the right treatment strategy. MRI is the only feasible image modality that can make that
566 distinction.

567
568 LHCF is currently a fracture that requires open surgery in most cases due to the radiographic inability to
569 distinguish stable injuries from unstable. This project seeks to use MRI without sedation or GA in order
570 to distinguish fracture patterns. MRI has been shown to be feasible in all age groups without the need
571 for sedation or GA [24].

572
573 Thévenin-Lemoine et.al. found that 25 of 27 children could successfully complete an MRI without
574 sedation or GA [23]. Of the 25 children, 17 (68%) had incomplete stable fracture patterns and six (24%)
575 had complete but minimally displaced fractures. In all, 23 (92%) children could be treated non-
576 operatively. Two children had unstable and displaced fractures and underwent surgery.

577
578 If proven safe and feasible, non-operative treatment for undisplaced and minimally displaced LHCF
579 would relieve the child of hospital admission, anesthesia and surgery and reduce parent's need for time
580 off work and reduce overall healthcare costs.

581
582 The investigators suspect a significant decrease in the need for operative management based on the
583 results of this project.

584 11 Risk analysis

585 The risks that occur in this study are associated with the general risks of non-operative treatment for
586 LHCF.

587 11.1 Treatment-related risks

588 Discomforts/risks from casting:

- 589 • Heat injury
- 590 • Pressure sores and skin breakdown
- 591 • Dermatitis
- 592 • Joint stiffness

593 11.2 Study disadvantages

594 Extra visits to the outpatient clinic. We follow all patients with seven visits to the outpatient clinic. This is
595 four more than with standard treatment and might be viewed as a disadvantage.

596 11.3 Study-related risks

597 11.3.1 Secondary displacement

598 During non-operative treatment of fractures, the risk of secondary displacement is well known. The risk
599 of secondary displacement of an initially undisplaced LHCF varies from 4% to more than 40%
600 depending on the initial stability and displacement [12]. As the initial stability in this study is evaluated by
601 MRI the investigators suspect that the risk of secondary displacement will be close to 4%.

602 **11.3.2 Radiation**

603 In comparison with the standard follow up of LHCF there are four additional visits to the out-patient clinic
604 with radiographs of the elbow in AP, ML and IO view. Collectively, the effective dosage is 0.004 mSv -
605 far below 0.1 mSv and is considered insignificant.

606 **11.3.3 Loss of privacy**

607 Patients' private and confidential medical information may get disclosed and confidentiality broken.
608

609 **11.4 Actions to minimize increased risks**

610 General treatment-related risks will be present whether the patient participates in the study or not. Such
611 risks will be managed by use of standards of treatment, i.e. casting by trained physicians and nurses.
612

613 Risk of unnoticed secondary displacement is lowered by an increased number of FUs with radiographs
614 and MRI in case of unstable injury.
615

616 The risk of loss of privacy and confidentiality will be managed by strict adherence to data safety and
617 security procedures explained elsewhere in this CIP.
618

619 The study will be implemented according to current valid international guidelines (ICH-GCP and ISO
620 14155). The ethical position is based on the Declaration of Helsinki, thus guaranteeing optimal
621 protection of patient interests.

622 **12 Informed consent process**

623 **12.1 Special considerations to consent pediatric patients**

624 In this pediatric study, the parent(s) or legal guardian(s) are informed face-to-face about the study and
625 provide informed consent using specific patient information and ICF. In any case, the child is informed
626 orally in an adequate way.
627

628 Written informed consent needs to be obtained from the parent(s) or legal guardian(s). Assent is
629 obtained from any child considered to be able to understand the basic information provided.
630

631 A member of the research team will, in an undisturbed environment, explain using a plain,
632 understandable language, movies and toys to each participant and parents the nature of the study, its
633 purpose, the procedures involved, the expected duration, the potential risks and benefits and any
634 discomfort it may entail.
635

636 Parents and children will be informed that the participation in the study is completely voluntary and that
637 they may withdraw from the study at any time and that withdrawal of consent will not affect subsequent
638 medical assistance and treatment.
639

640 The participant's parents will be informed that their child's medical records will be examined directly by
641 authorized individuals involved in the study.
642

643 Consent will be obtained from every patient's parents before any study-specific procedures or
644 assessments take place.
645

646 Parents will be provided specific information and ICF describing the study and providing sufficient
647 information for the parents to make an informed decision about their child's participation in the study
648 together with general information about participating in a research project from the Danish National
649 Committee on Health Research Ethics.

650
651 Parents will in most cases have at least 24 hours to consider enrollment however, there might be factors
652 (e.g. late presentation to the ED) that dictate more emergent treatment requiring consent with less
653 consideration time.

654
655 The parents will signify their willingness to let their child participate in the study by signing and dating a
656 personal copy of the approved ICF. The consent form must also be signed and dated by a member of
657 the research team and it will be retained as part of the study records. The investigator will keep the
658 original ICF in the ISF and provide the patient's parents with a copy.

659 **13 Adverse event reporting**

660 In this clinical investigation no medical devices are used and based on the risk analyses, AEs or serious
661 AEs (SAEs) according to ISO 14155 are not collected.

662 **14 Data management**

663 This project complies with the EU's General Data Protection Regulation (GDPR) according to the
664 Danish law on data protection *Databeskyttelsesloven* and *Databeskyttelsesforordningen*.

665
666 In order to plan and conduct visits we ask that consent is given to access the patient's EHR. We ask
667 permission to retrieve patient-related data and to read entries regarding visits. We ask permission to
668 access radiographs and MRIs. We ask that access the patient's EHR is given until the conclusion of the
669 project. No access to the patient's EHR regarding the study is made before informed consent to
670 participate is given.

671
672 Consent gives the person responsible for the trial and the relevant authorities direct access to obtain
673 information in the patient's medical records for the purpose of carrying out the project as well as for
674 control purposes.

675 **14.1 Data collection, source data, storage and archiving**

676 Data management will be performed by the PI. Data handling and protection are conducted according to
677 the ISO 14155 guidelines and ICH-GCP and applicable regulations.

678
679 The eCRF collects data from each participant. Specifically all data on each patient participating in the
680 study are documented in the eCRF. The eCRF contains data items as specified in this CIP. Modification
681 of the eCRF will be made only if deemed necessary and in accordance with any amendment to the CIP.

682
683 The patient's hospital records are stored securely in the hospital's EHR (Epic Systems Corporation,
684 Verona, Wisconsin, USA).

685 **14.1.1 Electronic CRF**

686 For this study, an eCRF is designed to accommodate the specific features of the study design. Access
687 to the eCRF is password protected. The project's eCRF is stored securely using Research Electronic
688 Data Capture (RedCAP, Vanderbilt University, USA). The eCRF is to be completed in a timely manner
689 after a patient's visit (i.e. 14 days after occurrence of a documentable event).

690 **14.2 Imaging data**

691 Radiographs and MRIs are stored securely in the hospital's Picture archiving and communication
692 system (PACS).

693 **14.3 Confidentiality**

694 Privacy and confidentiality of the patient's medical data will be maintained through the study.

695
696 Fully identifiable information may be reviewed for the purpose of verifying data in the eCRF. This can be
697 carried out by the PI. Personal medical information will be treated as confidential at all times. The
698 informed consent document will contain information about the confidentiality of the medical information
699 and approval for the access.

700 **15 Regulatory affairs**

701 The CIP, associated documents, investigator's financial disclosure, the patient information and ICFs will
702 be sent to a respective EC for evaluation and approval. The relevant EC will be kept informed about the
703 study progress and events according to their specific regulations and procedures.

704 **16 Disclosures and economy**

705 The initiative for this study has been taken solely by the investigators. The investigators and affiliated
706 colleagues have not received any financial payments or other benefits from any commercial entity
707 related to the subject of this project. The investigators declare that they have no conflict of interest.

708
709 Participants do not receive any economic benefits or gifts from the participation in this project.

710
711 All expenses are paid for by the sponsor.

712 **17 Patient insurance**

713 As with any treatment in the Danish healthcare system all patients are insured and covered by The
714 Patient Compensation Association (Patienterstatningen).

715 **18 Study report and publication policy**

716 **18.1 Final Study Report**

717 The results of the statistical evaluation will be summarized in a report, which forms the basis for the
718 comprehensive FSR. The comprehensive FSR forms the basis for all future publications.

719 18.2 Publication

720 The study protocol and the trial will be registered with Clinicaltrials.gov

721

722 The results, both positive, negative and inconclusive, will be sent for submission in a peer reviewed
723 international orthopedic journal, and the results will be presented at national and international scientific
724 meetings. Reporting will adhere to the STROBE guidelines for cohort studies [31].

725 19 Termination criteria

726 The progress of the study, in particular the enrollment and safety aspects, will be closely monitored
727 together with the sponsor. The sponsor may decide to terminate the. In case of an early study
728 termination, all patients already enrolled in the study will be followed up until the last FU visit as defined
729 in the CIP.

730 19.1 Stopping rules

731 The recruitment will be put on hold for safety reason if:

732

- 733 • Secondary displacement of more than 2 mm during FU in > 75% of cases at interim analysis.

734

735 In such a case, the reported complication will be discussed with the sponsor. The sponsor will decide
736 about the actions to be taken and if the study needs to be stopped or not.

737 20 Deviations from the Clinical Investigation Plan

738 Deviations from the procedures as described in this CIP or altering the CIP without following a defined
739 process are not permitted.

740

741 A CIP deviation is any non-adherence to the protocol that does not involve the inclusion/exclusion
742 criteria, primary efficacy variable, and GCP guidelines. CIP deviations are minor and do not impact the
743 study in a major way. CIP deviations are to be reported to the sponsor within ten working days.

744

745 A CIP violation is any significant divergence from the protocol on the part of the patient, investigator,
746 sponsor, or any other responsible party that affects e.g. the inclusion/exclusion criteria, primary efficacy
747 variable, or GCP guidelines. Violations will be recorded at the study site and in the eCRF.

748 21 Amendments to the Clinical Investigation Plan

749 No changes to the approved CIP are allowed, except when the change removes immediate threats for
750 the patient safety or is of a purely administrative or logistic nature.

751

752 Should there be any need during the performance of the study to change this CIP, an amendment will
753 be developed, issued and approved by or notified to the required bodies.

754

755

756

757 22 Time schedule

Ethics Committee approvals	28.06.2021	to	01.09.2021
First patient/first visit	01.10.2021		
Last patient/first visit	01.10.2023		
Last patient/last visit	01.10.2025		
Data analysis	01.11.2025	to	01.03.2026
Final Study Report	01.03.2026	to	01.06.2026

758 23 Authors

759 CIP developed by

760

PCI	Department of Orthopedic Surgery Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark
Project Manager	Morten Jon Andersen
Additional author(s)	Peter Søndergaard, MD Bo Sanderhoff Olsen, MD, ph.d., professor Jeppe Vejlgard Rasmussen, MD, ph.d.

761

762

763 CIP approval signatures

764

Name	Function	Date	Signature
Morten Jon Andersen	Principal Coordinating Investigator		

765

Name	Function	Date	Signature
Bo Sanderhoff Olsen	Director of institution		

766

767 With signing this statement, I agree and confirm:

- 768 • To have read and understood this CIP and to have informed and to have supervised the appropriate
- 769 training of all research team members of this study site involved with the conduct of the study.
- 770 • To assume responsibility to conduct the study in compliance with this protocol and future
- 771 amendments at this study site.
- 772 • To obtain written approval the independent EC before initiating the clinical investigation at this study
- 773 site.
- 774 • To not implement any changes to the protocol or the corresponding procedures without written
- 775 agreement from the sponsor and the EC, except where necessary to eliminate immediate risk to the
- 776 study patients.
- 777 • That I and all team members involved in the conduct of this clinical investigation are aware and
- 778 trained in aspects of ICH-GCP and all applicable regulatory requirements.

779 **24 Reference list**

- 780 1. Rang M, Pring ME, Wenger DR. Rang's Children's Fractures. 3. udg. Lippincott Williams &
781 Wilkins; 2005.
- 782 2. Kamegaya M, Shinohara Y, Kurokawa M, et al. Assessment of stability in children's minimally
783 displaced lateral humeral condyle fracture by magnetic resonance imaging. J Pediatr Orthop
784 1999;19:570–2.
- 785 3. Horn BD, Herman MJ, Crisci K, et al. Assessment of stability in children's minimally displaced
786 lateral humeral condyle fracture by magnetic resonance imaging. J Pediatr Orthop 2020;90:30–
787 5.
- 788 4. Horn BD, Herman MJ, Crisci K, et al. Fractures of the lateral humeral condyle: Role of the
789 cartilage hinge in fracture stability. J Pediatr Orthop 2002;22:8–11.
- 790 5. Beltran J, Rosenberg ZS, Kawelblum M, et al. Pediatric elbow fractures: MRI evaluation. Skelet
791 Radiol A J Radiol Pathol Orthop 1994;23:277–81.
- 792 6. Houshian S, Mehdi B, Larsen MS. The epidemiology of elbow fracture in children: Analysis of
793 355 fractures, with special reference to supracondylar humerus fractures. J Orthop Sci 2001;
- 794 7. Waters PM, Skaggs DL, Flynn JM (Jack), et al. Rockwood and Wilkins' fractures in children. 9.
795 udg. Wolters Kluwer; 2019.
- 796 8. Naranje SM, Erali RA, Warner WC, et al. Epidemiology of Pediatric Fractures Presenting to
797 Emergency Departments in the United States. J Pediatr Orthop 2016;36:e45–8.
- 798 9. Hedström EM, Svensson O, Bergström U, et al. Epidemiology of fractures in children and
799 adolescents: Increased incidence over the past decade: A population-based study from northern
800 Sweden. Acta Orthop 2010;81:148–53.
- 801 10. Rennie L, Court-Brown CM, Mok JYQ, et al. The epidemiology of fractures in children. Injury
802 2007;38:913–22.
- 803 11. Landin LA, Danielsson LG. Elbow fractures in children: An epidemiological analysis of 589
804 cases. Acta Orthop 1986;57:309–12.
- 805 12. Pirker ME, Weinberg AM, Höllwarth ME, et al. Subsequent displacement of initially nondisplaced
806 and minimally displaced fractures of the lateral humeral condyle in children. J Trauma - Inj Infect
807 Crit Care 2005;58:1202–7.
- 808 13. Abzug JM, Dua K, Kozin SH, et al. Current Concepts in the Treatment of Lateral Condyle
809 Fractures in Children. J Am Acad Orthop Surg 2019;00:1.
- 810 14. Song KS, Kang CH, Min BW, et al. Internal oblique radiographs for diagnosis of nondisplaced or
811 minimally displaced lateral condylar fractures of the humerus in children. J Bone Jt Surg - Ser A
812 2007;89:58–63.
- 813 15. Goodwin SJ, Irwin LJ, Irwin GJ. Gender differences in the order of appearance of elbow
814 ossification centres. Scott Med J 2019;64:2–9.
- 815 16. Shrader W, Campbell M, Jacofsky D. Accuracy of emergency room physicians' interpretation of
816 elbow fractures in children. Orthopedics Orthopedics; 2008;31:1177.
- 817 17. Milch H. Fractures and fracture dislocations of the humeral condyles. J Trauma - Inj Infect Crit
818 Care 1964;4:592–607.
- 819 18. Song KS, Chul HCK, Byung WM, et al. Closed reduction and internal fixation of displaced
820 unstable lateral condylar fractures of the humerus in children. J Bone Jt Surg - Ser A
821 2008;90:2673–81.

- 822 19. Song KS, Waters PM. Lateral condylar humerus fractures: Which ones should we fix? *J Pediatr Orthop* 2012;32:5–9.
823
- 824 20. Bast SC, Hoffer MM, Aval S. Nonoperative treatment for minimally and nondisplaced lateral
825 humeral condyle fractures in children. *J Pediatr Orthop* 1998;18:448–50.
- 826 21. Weiss JM, Graves S, Yang S, et al. A new classification system predictive of complications in
827 surgically treated pediatric humeral lateral condyle fractures. *J Pediatr Orthop* 2009;29:602–5.
- 828 22. Hailotte G, Bachy M, Delpont M, et al. The Use of Magnetic Resonance Imaging in Management
829 of Minimally Displaced or Nondisplaced Lateral Humeral Condyle Fractures in Children. *Pediatr
830 Emerg Care* 2017;33:21–5.
- 831 23. Thévenin-Lemoine C, Salanne S, Pham T, et al. Relevance of MRI for management of non-
832 displaced lateral humeral condyle fractures in children. *Orthop Traumatol Surg Res*
833 2017;103:777–81.
- 834 24. Runge SB, Christensen NL, Jensen K, et al. Children centered care: Minimizing the need for
835 anesthesia with a multi-faceted concept for MRI in children aged 4–6. *Eur J Radiol Elsevier*;
836 2018;107:183–7.
- 837 25. Hallowell LM, Stewart SE, De Amorim E Silva CT, et al. Reviewing the process of preparing
838 children for MRI. *Pediatr Radiol Pediatr Radiol*; 2008. s. 271–9.
- 839 26. Raschle NM, Lee M, Buechler R, et al. Making MR imaging child's play - Pediatric neuroimaging
840 protocol, guidelines and procedure. *J Vis Exp* 2009;29:1–6.
- 841 27. De Bie HMA, Boersma M, Wattjes MP, et al. Preparing children with a mock scanner training
842 protocol results in high quality structural and functional MRI scans. *Eur J Pediatr*
843 2010;169:1079–85.
- 844 28. Cahoon GD, Davison TE. Prediction of compliance with MRI procedures among children of ages
845 3 years to 12 years. *Pediatr Radiol* 2014;44:1302–9.
- 846 29. Ahmad R, Hu HH, Krishnamurthy R, et al. Reducing sedation for pediatric body MRI using
847 accelerated and abbreviated imaging protocols. *Pediatr Radiol Pediatr Radiol*; 2018;48:37–49.
- 848 30. Barnea-Goraly N, Weinzimer SA, Ruedy KJ, et al. High success rates of sedation-free brain MRI
849 scanning in young children using simple subject preparation protocols with and without a
850 commercial mock scanner-the Diabetes Research in Children Network (DirecNet) experience.
851 *Pediatr Radiol* 2014;44:181–6.
- 852 31. Vandembroucke JP, Von Elm E, Altman DG, et al. Strengthening the Reporting of Observational
853 Studies in Epidemiology (STROBE): Explanation and elaboration. *Epidemiology* 2007;18:805–
854 35.
- 855 32. Dill T. Contraindications to magnetic resonance imaging: non-invasive imaging. *Heart England*;
856 2008;94:943–8.
- 857 33. Tawfik AI, Kamr WH, Taman SE. Comparison of 2D Fat Suppressed Proton Density (FS-PD)
858 and 3D (WATS-c) MRI pulse sequences in evaluation of chondromalacia patellae. *Egypt J
859 Radiol Nucl Med* 2019;50:85.
- 860 34. Bitar R, Leung G, Perng R, et al. MR pulse sequences: What every radiologist wants to know but
861 is afraid to ask. *Radiographics* 2006. s. 513–37.
- 862 35. Morrey BF. *The elbow and its disorders*. Saunders; 2008.
- 863 36. Longo UG, Franceschi F, Loppini M, et al. Rating systems for evaluation of the elbow. *Br Med
864 Bull* 2008;
- 865 37. Cusick MC, Bonnaig NS, Azar FM, et al. Accuracy and reliability of the mayo elbow performance

- 866 score. J Hand Surg Am 2014;
- 867 38. Merkel, Voepel-Lewis, Shayevitz, et al. The FLACC: a behavioral scale for scoring postoperative
868 pain in young children. *Pediatr Nurs* 1997;23:293–7.
- 869 39. Hicks CL, Von Baeyer CL, Spafford PA, et al. The Faces Pain Scale - Revised: Toward a
870 common metric in pediatric pain measurement. *Pain* 2001;31:1177.
- 871 40. Bieri D, Reeve RA, Champion GD, et al. The faces pain scale for the self-assessment of the
872 severity of pain experienced by children: Development, initial validation, and preliminary
873 investigation for ratio scale properties. *Pain* 1990;41:139–50.
- 874 41. Huguet A, Stinson JN, McGrath PJ. Measurement of self-reported pain intensity in children and
875 adolescents. *J Psychosom Res* 2010;68:329–36.
- 876 42. Bailey B, Gravel J, Daoust R. Reliability of the visual analog scale in children with acute pain in
877 the emergency department. *Pain* 2012;153:839–42.
- 878

879 Appendix 1 - Diagnosis and Treatment Protocol

